- Home
- AIRT vs PRLD Comparison
AIRT vs PRLD Comparison
Compare AIRT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- PRLD
- Stock Information
- Founded
- AIRT 1980
- PRLD 2016
- Country
- AIRT United States
- PRLD United States
- Employees
- AIRT N/A
- PRLD N/A
- Industry
- AIRT Air Freight/Delivery Services
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- AIRT Consumer Discretionary
- PRLD Health Care
- Exchange
- AIRT Nasdaq
- PRLD Nasdaq
- Market Cap
- AIRT 63.8M
- PRLD 69.1M
- IPO Year
- AIRT N/A
- PRLD 2020
- Fundamental
- Price
- AIRT N/A
- PRLD $1.42
- Analyst Decision
- AIRT
- PRLD Strong Buy
- Analyst Count
- AIRT 0
- PRLD 3
- Target Price
- AIRT N/A
- PRLD $4.00
- AVG Volume (30 Days)
- AIRT 1.2K
- PRLD 290.5K
- Earning Date
- AIRT 11-11-2025
- PRLD 11-05-2025
- Dividend Yield
- AIRT N/A
- PRLD N/A
- EPS Growth
- AIRT N/A
- PRLD N/A
- EPS
- AIRT N/A
- PRLD N/A
- Revenue
- AIRT $296,309,000.00
- PRLD $7,000,000.00
- Revenue This Year
- AIRT N/A
- PRLD N/A
- Revenue Next Year
- AIRT N/A
- PRLD N/A
- P/E Ratio
- AIRT N/A
- PRLD N/A
- Revenue Growth
- AIRT 5.14
- PRLD N/A
- 52 Week Low
- AIRT $14.56
- PRLD $0.61
- 52 Week High
- AIRT $26.70
- PRLD $2.08
- Technical
- Relative Strength Index (RSI)
- AIRT 49.54
- PRLD 60.32
- Support Level
- AIRT $22.00
- PRLD $1.36
- Resistance Level
- AIRT $23.31
- PRLD $1.50
- Average True Range (ATR)
- AIRT 0.31
- PRLD 0.19
- MACD
- AIRT -0.20
- PRLD 0.01
- Stochastic Oscillator
- AIRT 30.96
- PRLD 48.91
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.